Rivaroxaban or Aspirin for Biological Aortic Prosthesis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.
Also called NCT02974920
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 1,000 participants
- Sponsor
- Registry
-
NCT02974920
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Unknown status
Technical summary
Registry record NCT02974920. Randomized; no masking; primary purpose prevention. Start 2017-01-01 (actual); primary completion 2022-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban or Aspirin for Biological Aortic Prosthesis
- Condition
- Aortic Stenosis
- Condition
- Aortic Regurgitation
- Condition
- Thrombosis
- Intervention (Drug)
- Rivaroxaban 10 MG
- Intervention (Drug)
- Aspirin
- Lead sponsor
- Christian Torp-Pedersen
- Collaborator
- Aalborg University Hospital
- Collaborator
- Aarhus University Hospital
- Collaborator
- Odense University Hospital
- Collaborator
- Copenhagen University Hospital, Rigshospitalet
Record details
- Record id
cardio:ct-nct02974920- Content hash
08b4217ce20509f83f3b8c930976c3b3dd6e0c153d8d25a8c44edbad9b89b22a